We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Changes in Cerebral Glucose Metabolism After Electroconvulsive Therapy (ECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01514435
Recruitment Status : Completed
First Posted : January 23, 2012
Last Update Posted : January 23, 2012
Information provided by (Responsible Party):
Medical University of Graz

Brief Summary:

There exist already a few studies that have measured changes of brain metabolism pre and post Electroconvulsive Therapy (ECT) by Positron emission tomography (PET) but these were all performed in a small number of patients and used different methodologies. It is therefore not surprising that these investigations provided inconsistent results, as reviewed previously {{23 Schmidt,E.Z. 2008}}.

In patients with treatment-refractory major depressive episodes, the investigators here therefore probed (a) whether changes in cerebral glucose metabolism measured by PET occur after treatment with ECT and (b) whether these correlate with the clinical amelioration of symptoms. To pursue this goal, the investigators assessed clinical effects, neurocognitive function, and brain metabolism using 18F-Fluoro-deoxyglucose (18F-FDG) PET at baseline and at the end of treatment.

Patients with a treatment refractory depression - defined as absent clinical improvement of depressive symptoms after at least two trials with antidepressants from different pharmacologic classes adequate in dose, duration of at least 6 weeks, and compliance {{30 Berlim,M.T. 2007}} - in whom ECT had been intended on clinical grounds were consecutively asked for participation in this study. Patients had to be between 18 and 80 years old and to be physically healthy.

Condition or disease Intervention/treatment
Major Depressive Disorder Device: Electroconvulsive therapy Device: 18-Fluoro-desoxy-glucose positron emission tomography

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Effects of Electroconvulsive Therapy in Severe Depression and Concomitant Changes in Cerebral Glucose Metabolism - an Exploratory Study
Study Start Date : May 2006
Primary Completion Date : May 2009
Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Dextrose
U.S. FDA Resources

Arm Intervention/treatment
Experimental: ECT verum group
Patients with treatment refractory depression treated with ECT
Device: Electroconvulsive therapy
treatment for major depression
Other Name: no other names
Device: 18-Fluoro-desoxy-glucose positron emission tomography

intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.

It´s a neuroimaging technique.

Other Name: no other names

Primary Outcome Measures :
  1. Brain glucose metabolism measured by FDG-PET [ Time Frame: one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical indication for ECT
  • treatment refractory depressive episode
  • age 18-85 y

Exclusion Criteria:

  • addiction as a first diagnosis
  • dementia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01514435

Medical University Graz; Department for Psychiatry
Graz, Styria, Austria, 8036
Sponsors and Collaborators
Medical University of Graz
Principal Investigator: Bernd Reininghaus Medical University of Graz

Responsible Party: Medical University of Graz
ClinicalTrials.gov Identifier: NCT01514435     History of Changes
Other Study ID Numbers: BRECT-2006-PET
First Posted: January 23, 2012    Key Record Dates
Last Update Posted: January 23, 2012
Last Verified: January 2012

Keywords provided by Medical University of Graz:
Electroconvulsive therapy
glucose metabolism

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms